American Journal of Hematology

The American Journal of Hematology provides broad coverage of experimental and clinical features of blood diseases in humans and in animal models of human disease. The journal publishes original contributions in non-malignant and malignant hematological diseases including clinical and basic studies in hemostasis and thrombosis, immunology, blood banking, and stem cell biology. Clinical translational reports describing novel therapeutic approaches to diagnosis and treatment of hematological diseases are welcomed and encouraged. The journal includes regular original laboratory and clinical research articles, brief research reports, critical reviews, images in hematology, letters and correspondence.

Publisher
Wiley
Website
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1096-8652
Impact factor
4.671 (2011)

Some content from Wikipedia, licensed under CC BY-SA

Oncology & Cancer

Blast count prognostic for CML presenting in advanced phase

(HealthDay)—Blast count seems to be the main prognostic count for patients with chronic myeloid leukemia (CML) presenting in an advanced phase, according to a study published online Aug. 27 in the American Journal of Hematology.

Oncology & Cancer

New score predicts risk for VTE in those with multiple myeloma

(HealthDay)—A new risk prediction score outperforms current guidelines for predicting venous thromboembolism (VTE) in multiple myeloma (MM), according to a study published online Aug. 4 in the American Journal of Hematology.

Oncology & Cancer

Octogenarians with acute myeloid leukemia have poor survival

(HealthDay)—Octogenarians with acute myeloid leukemia (AML) have a one-month mortality rate of 41 percent and overall survival (OS) of 1.5 months, according to a research letter published in the June issue of the American ...

Oncology & Cancer

Burden of myeloproliferative neoplasms in Australia revealed

New research led by Cancer Council Queensland and Curtin University has investigated the patterns and trends of a rare group of blood cancers known as myeloproliferative neoplasms (MPN) for the first time in Australia.

Diseases, Conditions, Syndromes

Fostamatinib seems effective for immune thrombocytopenia

(HealthDay)—Fostamatinib produces clinically meaningful responses in adults with immune thrombocytopenia (ITP), according a study published in the July issue of the American Journal of Hematology.

Diseases, Conditions, Syndromes

Rituximab effective for lupus-associated cytopenia

(HealthDay)—Rituximab treatment seems effective for systemic lupus erythematosus (SLE)-associated immune cytopenias, with an overall initial response rate of 86 percent, according to a study published online Dec. 16 in ...

Oncology & Cancer

VDT PACE effective in relapsed, refractory multiple myeloma

(HealthDay)—For heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM), bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide and etoposide (VDT PACE) regimen and its modifications ...

page 1 from 3